1050 related articles for article (PubMed ID: 15617852)
21. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
Suksomboon N; Poolsup N; Prasit T
J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Cao Z; Cooper ME
Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T
Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058
[TBL] [Abstract][Full Text] [Related]
24. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.
Jugdutt BI
Clin Interv Aging; 2010 Dec; 5():403-16. PubMed ID: 21152242
[TBL] [Abstract][Full Text] [Related]
25. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
26. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Ichikawa Y
Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
[TBL] [Abstract][Full Text] [Related]
28. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
[TBL] [Abstract][Full Text] [Related]
30. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
31. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
33. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
34. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
35. Telmisartan as a metabolic sartan for targeting vascular failure.
Inoue T; Node K
Expert Opin Pharmacother; 2008 Jun; 9(8):1397-406. PubMed ID: 18473713
[TBL] [Abstract][Full Text] [Related]
36. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
37. HIV protease inhibitors activate the adipocyte renin angiotensin system.
Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
39. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan for the reduction of cardiovascular morbidity and mortality.
Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]